Plasma osteoprotegerin and breast cancer risk in BRCA1 and BRCA2 mutation carriers

Emerging evidence suggests a role of receptor activator of nuclear factor κB (RANK)/RANK ligand (RANKL) signaling in breast cancer development. Lower osteoprotegerin (OPG) levels, the endogenous decoy receptor for RANKL which competes with RANK for binding of RANKL, has been reported among BRCA muta...

Descripción completa

Detalles Bibliográficos
Autores principales: Odén, Lovisa, Akbari, Mohammad, Zaman, Tasnim, Singer, Christian F., Sun, Ping, Narod, Steven A., Salmena, Leonardo, Kotsopoulos, Joanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5349945/
https://www.ncbi.nlm.nih.gov/pubmed/27893411
http://dx.doi.org/10.18632/oncotarget.13417

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5349945/
https://www.ncbi.nlm.nih.gov/pubmed/27893411
http://dx.doi.org/10.18632/oncotarget.13417

Ejemplares similares